Revelation Biosciences Taps Avance Clinical for Phase 2/3 TITAN Study in Acute Kidney Injury
- Revelation Biosciences selected Avance Clinical to manage the Phase 2/3 adaptive TITAN study evaluating Gemini (TLR4 agonist) in acute kidney injury, targeting enrollment start in Q4 2026.
- Avance will provide full clinical trial support including site identification, patient recruitment, safety monitoring, and data management across approximately 300 hospital-based renal patients.
- The engagement leverages Avance's recently expanded Asia Pacific footprint and GlobalReady multi-regional delivery model to support the adaptive design registration study.
Operational Impact
Avance Clinical secures a late-stage pivotal mandate for a U.S.-listed biotech sponsor, reinforcing its competitive position in adaptive Phase 2/3 registration studies and validating its expanded Asia Pacific clinical operations network.
Source: PharmaSource RSS